An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; KHK 2455 (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Kyowa Kirin Pharmaceutical Development
- 27 Sep 2019 Planned End Date changed from 25 May 2021 to 25 Feb 2022.
- 27 Sep 2019 Planned primary completion date changed from 31 Mar 2021 to 31 Dec 2021.
- 13 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Apr 2019 to 30 Sep 2019.